Allterum’s Antibody

4A10 and CD127 (also known as IL-7Rα) in Scientific Literature
Review highlighting oncogenic mutations in the IL-7 pathway
Mutations that collaborate with IL-7Ra signaling pathways to drive ALL. Advances in Biological Regulation (2021)
4A10 Preclinical Data by Dr. Scott Durum’s Group
IL-7R is highlighted for its potential oncogenic effects in T-cell ALL
IL-7R signaling can drive leukemia development, acceleration, and resistance to chemotherapy
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update Adv Biol Regul (2019)
Targeting IL-7R with an antibody-drug conjugate is efficacious in models of T-cell ALL
IL-7R may play a key role in driving Ph-like and Ph+ B-cell acute lymphoblastic leukemia
Glucocorticoid resistance is reversible with targeted inhibition of the IL-7 pathway
CD127 is a promising target for the treatment of pediatric acute lymphoblastic leukemia
ALLTERUM THERAPEUTICS
Advancing an innovative solution for a critical and unmet medical need